Literature DB >> 34000040

Obstructive sleep apnoea testing and management in atrial fibrillation patients: a joint survey by the European Heart Rhythm Association (EHRA) and the Association of Cardiovascular Nurses and Allied Professions (ACNAP).

Lien Desteghe1,2,3,4, Jeroen M L Hendriks5,6, Hein Heidbuchel1,3,4, Tatjana S Potpara7,8, Geraldine A Lee9, Dominik Linz6,10,11,12.   

Abstract

Obstructive sleep apnoea (OSA) is highly prevalent in atrial fibrillation (AF) patients and associated with reduced response to rhythm control strategies. However, there is no practical guidance on testing for OSA in AF patients and for OSA treatment implementation. We sought to evaluate current practices and identify challenges of OSA management in AF. A descriptive cross-sectional study was performed with a content-validated survey to evaluate OSA management in AF by healthcare practitioners. Survey review, editing, and dissemination occurred via the European Heart Rhythm Association and the Association of Cardiovascular Nursing and Allied Professions and direct contact with arrhythmia centres. In total, 186 responses were collected. OSA-related symptoms were ranked as the most important reason to test for OSA in AF patients. The majority (67.7%) indicated that cardiologists perform 'ad-hoc' referrals. Only 11.3% initiated systematic testing by home sleep test or respiratory polygraphy and in addition, 10.8% had a structured OSA assessment pathway in place at the cardiology department. Only 6.7% of the respondents indicated that they test >70% of their AF patients for OSA as a component of rhythm control therapy. Various barriers were reported: no established collaboration between cardiology and sleep clinic (35.6%); lack in skills and knowledge (23.6%); lack of financial (23.6%) and personnel-related resources (21.3%). Structured testing for OSA occurs in the minority of AF patients. Centres apply varying methods. There is an urgent need for increased awareness and standardized pathways to allow OSA testing and treatment integration in the management of AF. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Diagnosis; EHRA survey; Integrated care; Sleep apnoea; Treatment;  Atrial fibrillation

Year:  2021        PMID: 34000040     DOI: 10.1093/europace/euab109

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

Review 1.  The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation.

Authors:  Z Čarná; P Osmančík
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

2.  Undiagnosed sleep apnea in patients with atrial fibrillation: An underutilized opportunity for antiarrhythmic management.

Authors:  Maartje J M Hereijgers; Konstanze Betz; Sami O Simons; Dominik Linz
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-16

3.  Personalized management of sleep apnea in patients with atrial fibrillation: An interdisciplinary and translational challenge.

Authors:  Dominik Linz; Benedikt Linz; Dobromir Dobrev; Mathias Baumert; Jeroen M Hendriks; Jean-Louis Pepin; Thomas Jespersen
Journal:  Int J Cardiol Heart Vasc       Date:  2021-07-21

4.  Pharmacological inhibition of acetylcholine-regulated potassium current (I K,ACh) prevents atrial arrhythmogenic changes in a rat model of repetitive obstructive respiratory events.

Authors:  Benedikt Linz; Anne Hauge Thostrup; Arnela Saljic; Karlijn Rombouts; Julie Norup Hertel; Mathias Hohl; James Milnes; Jacob Tfelt-Hansen; Dominik Linz; Thomas Jespersen
Journal:  Heart Rhythm O2       Date:  2021-11-19

5.  Obstructive respiratory events during procedural sedation and analgesia: Another WHY to routinely screen for sleep apnea before catheter ablation of atrial fibrillation.

Authors:  Dominik Linz; Benedikt Linz; Marloes Homberg; Esther Bouman; Dobromir Dobrev; Jeroen M Hendriks; Sami O Simons
Journal:  Int J Cardiol Heart Vasc       Date:  2021-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.